Multiple dose clinical trial (sequential x 72 hour applications)
• World’s first patch to deliver therapeutic levels of oxymorphone transdermally
• 2 sequential patch application (in n=12), mean CMAX increases, Consistent delivery profile, Well tolerated, minimal irritation
• 75% less oxymorphone required for pain administration vs. oxymorphone ER oral tablets over the same 72 hour period
Multiple dose clinical trial (sequential x 72 hour applications)...
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add POH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| POH (ASX) Chart |
Day chart unavailable
